4,831 Shares in Eli Lilly and Company $LLY Purchased by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD

Key Points

• Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired 4,831 Eli Lilly shares worth approximately $5.79 million during the second quarter. Institutional investors collectively own 82.53% of the company.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $1,295.39; 24 analysts rate the stock a Buy, while one rates it a Sell.
• Eli Lilly reported quarterly earnings of $8.38 per share and revenue of $22.97 billion, exceeding estimates, while revenue rose 47.7% year over year. The company also declared a quarterly dividend of $1.73 per share, representing a 0.6% annualized yield.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,831 shares of the company's stock, valued at approximately $5,794,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company's stock valued at $32,000 after purchasing an additional 24 shares during the period. Maseco LLP grew its holdings in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after purchasing an additional 28 shares during the period. Finally, Mcguire Capital Advisors Inc. purchased a new stake in Eli Lilly and Company in the fourth quarter worth $38,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LLY shares. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a "buy" rating in a research note on Tuesday, June 9th. Guggenheim increased their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Leerink Partners lifted their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an "outperform" rating in a report on Thursday, June 25th. Wolfe Research restated an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, HSBC upped their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,295.39.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,122.74 on Friday. The stock's 50-day simple moving average is $1,185.52 and its 200 day simple moving average is $1,072.89. The stock has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 1.39 and a beta of 0.50. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52-week low of $712.05 and a 52-week high of $1,292.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Friday, August 14th were given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is 23.22%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s GLP-1 franchise is described as growing at nearly 50% annually, supporting the company’s recent rise above a $1 trillion market capitalization. Analysts and commentators continue to see attractive medium-term prospects from strong demand for obesity and diabetes treatments. Eli Lilly Stock Has Become a Trillion-Dollar Giant
• Positive Sentiment: Coverage highlights Lilly’s broadening pipeline, with profits from incretin drugs helping fund development of the next generation of medicines. The company is also expected to use GLP-1 proceeds to expand into women’s health, potentially creating additional long-term growth avenues. Eli Lilly’s pipeline in 2026
• Positive Sentiment: Reports that Lilly rationed some launches because demand exceeded supply underscore the commercial strength of its products, although they also highlight the importance of expanding manufacturing capacity. What Eli Lilly Was Telling You While It Rationed Its Own Launches
• Neutral Sentiment: Articles comparing Lilly with Nvidia and projecting the value of long-term investments remain favorable toward Lilly’s growth story, but they are opinion pieces and do not introduce a new near-term earnings catalyst. Got $10,000? Eli Lilly vs. Nvidia
• Negative Sentiment: Investors are increasingly focused on whether Lilly’s valuation already reflects much of its GLP-1 success. The recent pullback and concerns about competition, supply, pipeline execution and the difficulty of sustaining rapid growth may be limiting upside and weighing on the stock. Eli Lilly Stock Has Become a Trillion-Dollar Giant

Insider Activity at Eli Lilly and Company

In other news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its portfolio includes treatments for diabetes and obesity, oncology, immunology, neuroscience, cardiovascular disease and other areas of significant unmet medical need.

The company's products include Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, and insulin products such as Humalog. Lilly also markets Verzenio for certain breast cancers and Kisunla for the treatment of early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.